Due to the seemingly insatiable appetites of companies like
Teva (NYSE:
TEVA),
Mylan (Nasdaq:
MYL) and
Watson (NYSE:
WPI),
there aren't nearly as many independent publicly-traded generic drug
companies as there used to be. While scarcity value alone is not a good
argument for considering
Hi-Tech Pharmacal (Nasdaq:
HITK),
this company's focus on higher-barrier products and over-the-counter
(OTC) cold and cough business, coupled with little sell-side support,
could make it a potential hidden gem at some point.
Continue here:
http://stocks.investopedia.com/stock-analysis/2012/Hi-Tech-Pharmacal-An-Under-Followed-Name-Worth-Following-HITK-PRX-TEVA-WCRX0712.aspx
No comments:
Post a Comment